(National Monitor) – Orexigen Therapeutics saw its shares skyrocket to its highest point in 18 months after declaring that its diet pill, Contrave, had benefits to the body’s cardiovascular system — but regulators aren’t happy with that announcement. Orexigen claimed that patients using Contrave had fewer adverse cardiovascular events or deaths than patients on a […]
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.